Baseline Characteristics of Contemporary Trial Participants with Heart Failure and Reduced Ejection Fraction: The VICTOR Trial
The VICTOR trial enrolled the most optimally treated population in a phase III heart failure trial. These features will facilitate assessment of the benefit of vericiguat and elucidate the outcomes of patients on up-to-date medical therapy.
Authors
- Clara Saldarriaga (ORCID: https://orcid.org/0000-0002-5945-1127)
- Justin Adrian Ezekowitz (ORCID: https://orcid.org/0000-0002-2724-4086)
- Piotr Ponikowski (ORCID: https://orcid.org/0000-0002-3391-7064)
- Stefano Corda (ORCID: https://orcid.org/0000-0002-8765-2444)
- Javed Butler (ORCID: https://orcid.org/0000-0001-7683-4720)
- Eldrin F. Lewis
- Yogesh N.V. Reddy (ORCID: https://orcid.org/0000-0001-5322-0902)
- JoAnn M. Lindenfeld (ORCID: https://orcid.org/0000-0001-9207-3634)
- Ciaran J. McMullan (ORCID: https://orcid.org/0000-0001-7269-6391)
- Robert John Mentz (ORCID: https://orcid.org/0000-0002-3222-1719)
- Kevin J. Anstrom (ORCID: https://orcid.org/0000-0001-6452-2172)
- Adriaan A. Voors (ORCID: https://orcid.org/0000-0002-5417-4415)
- James E. Udelson (ORCID: https://orcid.org/0000-0003-2998-910X)
- Marc P. Bonaca (ORCID: https://orcid.org/0000-0002-9860-3584)
- Michele Senni
- Carolyn Lam
- Mahesh J. Patel
- Aiwen Xing
- Giuseppe M.C. Rosano
- Christopher M. O’Connor (ORCID: https://orcid.org/0000-0002-1076-718X)
- Faiez Zannad
- Davis Gates
Institutions
- University of North Carolina at Chapel Hill (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Tufts Medical Center (US)
- Vita-Salute San Raffaele University (IT)
- University of Alberta (CA)
- University of Groningen (NL)
- Università degli studi di Cassino e del Lazio Meridionale (IT)
- San Raffaele University of Rome (IT)
- University of Mississippi (US)
- Wroclaw Medical University (PL)
- Clinical Research Institute (US)
- Municipality of Medellín (CO)
- Ospedale Papa Giovanni XXIII (IT)
- National University Heart Centre Singapore (SG)
- Baylor Medical Center at Garland (US)
- Canadian VIGOUR Centre (CA)
- Bayer (Switzerland) (CH)
- Mayo Clinic in Arizona (US)
- IRCCS Ospedale San Raffaele (IT)
- National Heart Centre Singapore (SG)
- Alaska Heart and Vascular Institute (US)
- Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT)
- University of Colorado Anschutz Medical Campus (US)
- University of Milano-Bicocca (IT)
- Université de Lorraine (FR)
- Vanderbilt University Medical Center (US)
- University of Colorado Denver (US)
- Stanford University (US)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-02-16
- DOI
- https://doi.org/10.1002/ejhf.3598
- Citations
- 17
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 23.60
Funders
- Eli Lilly and Company
- AstraZeneca
- Bayer
- Sanofi
- Heart Failure Society of America
- Regeneron Pharmaceuticals
- Impulse Dynamics